Dapagliflozin in type 2 diabetes with cardiovascular disease (Poland, Phase 3)

Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing Dapagliflozin 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: Mean percent change in body weight from baseline to week 24 (dapagliflozin 10 mg vs placebo). Started Jan 2010; status: completed.